Advertisements

Chloral Hydrate

Quick links to important sections

Chloral Hydrate

Advertisements
Advertisements

Treatment option: Insomnia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Chloral Hydrate

Quick Facts

Property Description
Active ingredient Chloral hydrate (Trichloroacetaldehyde monohydrate)
Form Capsule, Oral solution (Syrup), Rectal suppository
Pharmacological class Sedative-Hypnotic, Central Nervous System (CNS) Depressant
Common use Inducing sleep (insomnia) and sedation
Origin Synthetic, Halogenated Hydrocarbon Derivative

What is Chloral Hydrate and its Pharmacological Classification?

Chloral hydrate is a foundational, synthetic prescription medicine defined chemically as 2,2,2-Trichloroethane-1,1-diol, a halogenated hydrocarbon derivative (C2H3Cl3O2). It is officially categorized as a sedative-hypnotic and CNS depressant, with its effect arising from the rapid conversion to its primary active metabolite, trichloroethanol, following administration. This classification reflects its core function: to slow widespread activity within the central nervous system by potentiating inhibitory signals. This action is clinically recognized and helps quiet the brain, supporting its use for achieving mental quiescence. As a single-entity product, Chloral hydrate is an older, distinct chemical entity that falls under the miscellaneous anxiolytics and sedatives group, distinguishing it from more recently developed analogues like benzodiazepines.


Composition, Forms, and General Therapeutic Purpose

The sole active ingredient in the pharmaceutical preparation is the INN, Chloral hydrate itself. The medication is commonly supplied in several pharmaceutical preparations, including a capsule form and a liquid oral solution or syrup, which typically utilize an aqueous-based vehicle, allowing for administration via the oral route. Its availability in syrup form provides a distinctive advantage, facilitating administration to patient groups, such as children requiring sedation before a procedure, who cannot easily swallow capsules. The general purpose of this substance is to generate rapid sedation or to induce a state of deep, short-term sleep, providing effective control over acute situations requiring mental calmness, a primary benefit widely known to achieve mental quiescence for short-term relief of severe insomnia.

Regulatory References

  1. Chloral Hydrate Drug Information
Advertisements

What side effects are possible with Chloral Hydrate?

Possible Side Effects and Safety Information

Official regulatory documents classify the medicine's safety profile based on the physiological systems affected and the frequency of adverse reactions. The most common effects involve the Nervous System and the Gastrointestinal System. Common reactions reported in regulatory sources include somnolence (drowsiness), confusion, nausea, and vomiting. Less common reactions may involve symptoms such as ataxia (clumsiness), dizziness, and skin rashes.

Serious adverse reactions, though rare, are documented in official labeling and include potentially life-threatening cardiac arrhythmias, severe hypersensitivity reactions such as Stevens-Johnson syndrome (SJS), and severe blood dyscrasias like agranulocytosis.

Safety constraints exist for vulnerable populations and pre-existing conditions. The medicine is officially contraindicated in individuals with severe hepatic or renal impairment due to the risk of active metabolite accumulation and toxicity. Older adults may be more susceptible to CNS effects such as confusion and ataxia. In pediatric patients, paradoxical excitement is a noted safety pattern.

Duration-related safety patterns are explicitly stated: the use of Chloral Hydrate is associated with the potential development of tolerance and physical and psychological dependence upon prolonged or repeated exposure. Furthermore, the label advises against co-administration with alcohol and other CNS depressants due to enhanced systemic effects.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Chloral Hydrate is characterized by profound toxicity affecting the central nervous system (CNS) and cardiovascular system, necessitating immediate emergency action. Regulatory guidance requires that immediate medical attention must be sought for any suspected overdose.

Manifestation Category Documented Clinical Presentations
CNS and Respiratory Profound CNS depression progressing to stupor and coma; severe respiratory depression and hypothermia.
Life-Threatening Outcomes Severe cardiac arrhythmias (including Ventricular Fibrillation), Cardiac Arrest, severe hypotension, and potential for acute renal failure or hepatic necrosis.

The documented profile mandates contacting emergency services immediately due to the risk of life-threatening events. Management, described as symptomatic and supportive treatment in official regulatory documents, must include continuous ECG monitoring due to the high risk of severe arrhythmias. There is no specific antidote known for Chloral Hydrate toxicity. Interventions such as gastric lavage and administration of activated charcoal may be considered in a hospital setting to limit further systemic absorption. Hospital monitoring of vital signs and respiratory function is required until the patient’s condition stabilizes.

Advertisements

Therapeutic Uses of Chloral Hydrate

Chloral Hydrate is generally considered relevant for easing symptoms associated with acute or episodic changes where supportive symptom management is appropriate. The medicine is commonly used to help with certain distressing symptoms across two key therapeutic domains.

Support for Acute and Severe Sleep Disturbances

This medicine is applied across domains where short-term symptom management is appropriate, primarily addressing symptoms of severe insomnia that interfere with functional stability. It helps address symptom clusters that may become intense, such as difficulty falling asleep or maintaining continuous sleep. This provides supportive relief that helps maintain a sense of stability during difficult episodes by easing the overall symptom load and may contribute to supporting rest.

The primary therapeutic indications are for short-term treatment of severe insomnia and calming before specific medical procedures.

Facilitation of Medical and Diagnostic Procedures

The drug is relevant in contexts marked by increased discomfort or tension, such as the situational anxiety and agitation preceding medical or dental interventions. This application helps address symptoms related to heightened physiological activity, especially in pediatric patients. Through its role in managing heightened physiological activity, it offers symptomatic relief that assists with managing symptoms that interfere with necessary functional stability during procedures.


Quick Fact: Symptom Management Contexts

Domain Conditions/Symptoms Benefit Focus
Procedural Support Situational anxiety, agitation, restlessness Assists with functional stability
Sleep Management Severe sleeplessness, difficulty falling asleep Contributes to supportive rest and stability

Regulatory References

  1. established clinical documentation
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Chloral Hydrate?

This information reflects official regulatory statements regarding eligibility and contraindications for Chloral Hydrate.

Classification Populations and Conditions
Contraindicated (Must Not Use) Marked hepatic (liver) impairment; marked renal (kidney) impairment or renal failure; severe cardiac (heart) disease; known hypersensitivity or allergy to the drug; active gastritis, esophagitis, or gastric/duodenal ulcers (for oral forms).
Use Not Generally Recommended / Caution Children and Adolescents: Use is generally restricted, requires specialist supervision, and is not recommended unless for short-term treatment of severe insomnia associated with a suspected or definite neurodevelopmental disorder, where other therapies have failed. Children under 2 years are not recommended due to unestablished safety and efficacy. Older Adults: Increased risk of side effects like confusion and excessive drowsiness; the lowest effective dose should be considered.
Physiological/Clinical Restrictions Patients with a history of drug or alcohol abuse; those with mental/mood conditions like depression or suicidal thoughts; caution is advised with mild to moderate hepatic or renal impairment; long-term use is associated with a risk of dependence.

Chloral Hydrate is classified as a Schedule IV controlled substance due to the potential for abuse and dependence, which imposes regulatory constraints on its use and prescribing.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Chloral Hydrate defines interaction patterns based on pharmacodynamic potentiation and mandated monitoring requirements when co-administered with other substances.

Pharmacodynamic Interactions and Prohibitions

Due to its classification as a CNS depressant, Chloral Hydrate has documented interactions leading to an enhancement of central depressive effects. Co-administration with Alcohol or other CNS depressants (including sedative antihistamines, antipsychotics, anxiolytics, and narcotic analgesics) must be avoided due to the potentiation of sedation. The combination with Sodium Oxybate is strictly restricted or formally contraindicated in regulatory guidance. Furthermore, co-use with medicinal products that prolong the QT interval in ECG increases the documented risk of cardiac arrhythmias.

Exposure Monitoring and Specific Restrictions

When Chloral Hydrate is co-administered with Coumarin anticoagulants (such as Warfarin), official guidance requires careful monitoring of the prothrombin time whenever the dose is initiated, changed, or discontinued. This reflects a documented need to observe changes in the anticoagulant effect. A specific sequence restriction exists with intravenous Furosemide: administration of Chloral Hydrate followed by Furosemide may result in a hypermetabolic state marked by symptoms like hypertension. For elderly patients, co-administration with Psychotropics or Anticholinergics carries a heightened, documented risk of Delirium.

Advertisements

Mechanism of Action

Chloral hydrate functions as a prodrug that must first be rapidly converted, primarily in the liver, into its active metabolite, trichloroethanol. This chemical transformation is a mandatory first step, as trichloroethanol is the molecular agent that carries out the drug's effect by engaging its primary biological target in the brain.

The active compound acts as a positive allosteric modulator on the brain's GABA-A receptors, which are the main control points for inhibitory signaling. By enhancing the activity of the inhibitory neurotransmitter GABA, this mechanism increases the flow of chloride ions ( Cl^-) into nerve cells, directly reducing the cell's ability to fire an electrical impulse.

The widespread reduction in neuronal excitability across the central nervous system culminates in a generalized CNS depression cascade. This systemic damping of nerve signaling produces a physiological state of generalized central nervous system depression, which accounts for the drug's overall physiological activity.

Advertisements

Dosage and Administration Information

Instruction Map: How to use Chloral Hydrate

This map formalizes the usage patterns and required procedural steps for administering chloral hydrate.


Administration Scope

Feature General Administration Guidelines
Route of administration: Oral (capsules or solution) and Rectal (via suppository or retention enema).
Dosing schedule: Adult Hypnotic: 500 mg to 1000 mg as a single dose. Maximum adult dose is 2 grams per day. Pediatric Sedation: Dosing is weight-based, typically 25 mg/kg to 75 mg/kg for procedural use.
Timing in relation to meals: The lower 250 mg sedative dose regimen is administered after meals three times daily.
Preparation requirements: The oral solution must be diluted with a liquid such as water, milk, or fruit juice immediately prior to intake to mitigate irritation.
Age-group administration rules: Geriatric Patients typically start with a lower 250 mg dose. Use is not recommended in children under 2 years and, if administered in children, requires medical specialist supervision.
Missed-dose rules: If a dose is forgotten, it must be omitted, and the standard schedule should be resumed at the next designated time (do not take two doses at once).
Special procedural conditions: For pre-procedure use, the dose is administered 30 to 60 minutes prior to the procedure. Treatment is limited to short-term use, not to exceed 2 weeks.

Resulting Procedural Structure

Step sequence:

  • Measure the dose according to the specific patient's regimen and maximum limits (up to 1000 mg for hypnotic use).
  • Dilute the measured oral solution with water or juice immediately before administration.
  • Administer the dose at the required time: 15 to 30 minutes before bedtime for hypnotic use, or after meals for sedative use.
  • Adhere strictly to the maximum course duration of 14 days.
  • If discontinuing after prolonged use, a gradual dose tapering is required.

Connection to the overall use protocol: Established clinical protocols define a precise sequence that governs the selection of the administration route, the numerical dosage, and adherence to maximum daily limits. This protocol is further defined by time-sensitive instructions—such as the pre-bedtime timing—and mandates the preparation steps like dilution prior to intake. These constraints ensure the medicine is utilized as intended according to established usage patterns.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Chloral Hydrate

Evidence for use in Procedural Sedation

Research was focused on evaluating outcomes related to stillness during medical and diagnostic procedures, particularly in children. This area includes Randomized Controlled Trials (RCTs) and systematic reviews. Research has specifically explored its application in pediatric patients undergoing procedures, such as neurodiagnostic testing and imaging (MRI, CT), where stillness is a monitored outcome.

Researchers examined specific outcomes related to functional stability during the procedure. These included the measured rate of procedural completion, the time it took to reach adequate sedation, and the total measured duration of response. Studies reported measurements for a successful completion rate of procedures, which is one of the outcomes monitored. Key limitations include issues in blinding the treatment and sample sizes were often modest in individual trials. The certainty of comparative findings is frequently cited as a limitation due to the heterogeneity of the evidence base.

Evidence for use in Short-Term Sleep Management

Research exploring its use for short-term sleep problems is derived primarily from older clinical trials and observational case series in highly specific patient groups. This research examined outcomes related to sleep measurement, such as the amount of time taken to fall asleep (sleep latency) and the overall duration of sleep achieved. Much of the evidence base for general insomnia is derived from older research, and research limitations frequently cite the age of the data. The observational studies often have small sample sizes and lack a control group.

What is Still Uncertain About Chloral Hydrate Research

Evidence highlights that much of the non-procedural evidence is derived from older research methodologies. The overall evidence quality varies across studies, particularly in comparative studies. Data for certain groups remain insufficient, and there are noted gaps in understanding the full implications of its use on neurodevelopmental follow-up in children. The limited information available for long-term outcomes means that areas related to chronic use require further exploration.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Chloral Hydrate (FAQ)


Q: How is Chloral Hydrate different from common sleeping pills?

Official documents classify this medicine as a sedative-hypnotic and a type of halogenated hydrocarbon derivative, which is a distinct chemical class from newer prescription sleeping medicines like benzodiazepines. Its effect is produced by its active metabolite, trichloroethanol, which works on the brain's GABA-A receptors to encourage general quietude.

Q: Does Chloral Hydrate cause the same kind of dependency as benzodiazepines?

Regulatory guidance notes that Chloral Hydrate is associated with the potential for developing tolerance and physical and psychological dependence, particularly if it is used for a prolonged time. This potential is reflected in its classification as a Schedule IV controlled substance, which imposes strict regulatory constraints on its use.

Q: Can Chloral Hydrate be taken if I am also taking an antidepressant?

Official documents caution that Chloral Hydrate can interact with other CNS depressants and certain psychotropic medicines, which may include some antidepressants. The combination with psychotropic medicines, which may include some antidepressants, is associated with a reported risk of enhanced sedative effects or mental confusion. The risk of effects like delirium is particularly heightened in older adults.

Q: Has there been recent research on the use of Chloral Hydrate for medical procedures?

Research summaries describe studies that have evaluated the medicine’s use for procedural sedation, especially in children undergoing diagnostic imaging where stillness is necessary. While outcomes like the time it took to reach sedation were measured, official reviews often indicate that the evidence base is generally older and the quality of evidence can vary.

Q: Can Chloral Hydrate affect my ability to drive or operate machinery (general caution)?

Yes, official labeling explicitly advises that due to common side effects such as somnolence (drowsiness), dizziness, and confusion, the medicine may impair a person's ability to safely drive a vehicle or operate complex machinery.

Q: Can I become tolerant to Chloral Hydrate quickly?

Regulatory text states that the potential for tolerance to the hypnotic effect exists, particularly when the medicine is used repeatedly or for a long period. The medication's regulatory labeling limits its use to a short duration, reflecting an approach to help mitigate the potential risk of tolerance development.

Q: Are there specific foods or drinks that should be avoided when using Chloral Hydrate?

Official instructions state that the oral solution is to be diluted with a liquid, such as water, milk, or fruit juice, immediately prior to intake. This dilution step is intended to address the potential for gastric irritation. Furthermore, regulatory sources strictly warn that alcohol must be avoided while using this medicine.

Q: What kind of monitoring is typically required when a person uses Chloral Hydrate?

Official guidance indicates that careful monitoring of the patient's prothrombin time is needed when Chloral Hydrate is used alongside certain Coumarin anticoagulants (blood thinners). The contraindications for use in severe hepatic (liver) or renal (kidney) impairment also necessitate a general awareness of the patient’s organ function.

Q: Are allergic reactions to Chloral Hydrate common?

Hypersensitivity (allergic reactions) is listed as a condition that prevents the use of this medicine. Official documents have documented severe reactions, such as Stevens-Johnson syndrome (SJS), as serious adverse events. However, regulatory sources generally do not provide a precise frequency for all types of allergic reactions.

Q: What is the recommended approach if another medicine is started while using Chloral Hydrate?

Given the medicine's potential for dangerous interactions, regulatory labeling reinforces the importance of disclosing all current and new medicines to a healthcare provider. This allows for the proper assessment of potential interactions before a medication change is implemented.

Q: Is Chloral Hydrate recommended for use during pregnancy?

Official drug labeling notes that studies in animals have shown an adverse effect on the fetus, and that there are no adequate and well-controlled studies in pregnant humans. It is generally classified as Pregnancy Category C.

Q: Are headaches a known side effect of Chloral Hydrate?

Regulatory lists of adverse reactions sometimes include headache in the general or less common category of side effects. The most frequently reported side effects are usually related to the nervous system, such as drowsiness and confusion.

Q: Is Chloral Hydrate used for pain management?

No, the official therapeutic indications for Chloral Hydrate are limited to inducing sleep (insomnia) and as a sedative prior to medical or surgical procedures. Pain management is not included in the authorized uses outlined in regulatory labeling.

Q: What should I do if I experience a very unusual reaction after using Chloral Hydrate?

Official protocol is for all suspected adverse events with a regulated product to be reported to the national drug authority’s adverse event program. For example, in the US, this is handled through the FDA's MedWatch program.

Q: Is it normal to feel a change in taste after taking Chloral Hydrate?

Official documents list taste disturbance (also known as dysgeusia) as a documented adverse reaction associated with the use of the medicine. Although this reaction is noted, it is typically described as an infrequent side effect.

Q: Does the form of Chloral Hydrate (liquid vs. capsule) affect how quickly it works?

Regulatory documents describe that the medicine must be rapidly converted to its active metabolite, trichloroethanol, for the sedative effect to occur. The official description of its rapid onset of action (typically 30–60 minutes) applies to the overall use, regardless of the authorized administration route or form.

Q: What is the official term for how the body handles Chloral Hydrate?

The official scientific term used to describe how the body processes the medicine, which includes its absorption, distribution, metabolism (conversion to active form), and elimination, is Pharmacokinetics (PK).

Q: What is the difference in action between Chloral Hydrate and barbiturates?

Regulatory texts describe Chloral Hydrate’s mechanism as acting via its metabolite trichloroethanol to enhance the activity of the inhibitory neurotransmitter GABA at the GABA-A receptor. While barbiturates are also known to affect this same receptor system, official labeling focuses on Chloral Hydrate's distinct action as a GABA-A positive allosteric modulator.

Q: Does Chloral Hydrate affect the normal sleep cycle?

Research reviews often describe the medicine's impact on sleep architecture. Studies have noted that while it successfully reduces the time it takes to fall asleep (sleep latency) and increases the total sleep duration, it may also be associated with a reduction in REM sleep phases.

Q: How is the safety of Chloral Hydrate monitored after it's approved?

Regulatory agencies require ongoing safety monitoring of approved medicines through a process called pharmacovigilance. This system relies on healthcare professionals and patients to report suspected adverse events, and the collected safety information is continually reviewed by the regulator.

Q: Is it true that Chloral Hydrate can affect blood sugar levels?

Official adverse event lists sometimes document disturbances in blood glucose or metabolism/nutrition disorders as a potential, though usually rare, effect of the medicine.

Q: What do official sources say about the potential for overdose with Chloral Hydrate?

Official labeling includes an explicit section on Overdosage, which details the signs and symptoms of a toxic dose, such as profound coma, respiratory depression, and severe heart rhythm problems. This section also provides the general principles for managing such an event.

Advertisements

How should Chloral Hydrate be stored and disposed of?

Storage and Disposal of Chloral Hydrate

The storage of Chloral Hydrate must adhere strictly to regulatory conditions to maintain its integrity and safety. The product should be stored at controlled room temperature, specifically below 25 C (77 F), and must be kept in a cool, dark place [Source 1.4, 1.6, 2.4]. It is mandatory to protect the medicine from light and to not freeze liquid solutions [Source 1.4, 2.3, 2.4].

The medication must remain in its original container, which should be kept tightly closed [Source 2.4]. The shelf life for some oral solutions is limited to 28 days after first opening [Source 1.4, 2.8]. Due to its controlled substance status, the product must be stored securely and kept out of the sight and reach of children [Source 1.8, 2.4].

For disposal, unused or expired Chloral Hydrate must be handled in accordance with local requirements [Source 1.4, 1.6]. Regulatory guidelines explicitly state that the medicine should not be disposed of via waste water or household trash and should be returned to the pharmacist [Source 2.2, 2.8].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Chloral Hydrate found in:

A-Z Index: